# A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

> **NCT03999697** · PHASE1 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Primary Cutaneous Follicle Centre Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Mantle Cell Lymphoma
- Plasma Cell Neoplasm
- B Cell Lymphoma

## Interventions

- **DRUG:** Autologous chimeric antigen receptor T cell transfusing agent targeting CD22

## Key facts

- **NCT ID:** NCT03999697
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2019-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03999697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03999697, "A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03999697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*